Evaluation of Crestor® (Rosuvastatin) in Daily Practice

Open-Label Non-Interventional Evaluation of Efficacy of Crestor® (Rosuvastatin) in Reduction of LDL-Cholesterol and Cardiovascular Risk Parameters in Patients With Hypercholesterolaemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00837083

Enrollment

602

Registered

2009-02-05

Start date

2007-01-31

Completion date

2007-10-31

Last updated

2009-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

hypercholesterolemia, cholesterol, LDL-cholesterol, rosuvastatin, Crestor

Brief summary

This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin) in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with hypercholesterolemia. Effectiveness is to be evaluated using the difference in LDL cholesterol level between the first and the second visit after 12 weeks.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* a patient with hypercholesterolemia who has been prescribed Crestoraccording to physician's judgement, irrespective of the inclusion in the study. * no treatment with any statin in the last 3 months

Exclusion criteria

* hypersensitivity to rosuvastatin or any other ingredient of Crestor * active liver disease, severe renal insufficiency * myopathy or predisposing risk factors for myopathy/ rhabdomyolysis * woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
LDL-cholesterol reduction	12 weeks

Secondary

Measure	Time frame
change in coronary risk	12 weeks
achievement of target levels of total cholesterol and LDL-cholesterol	12 weeks
patient compliance	12 weeks

Outcome results